LV11596B - Long-acting injection susoensions and a process for their preparation - Google Patents

Long-acting injection susoensions and a process for their preparation Download PDF

Info

Publication number
LV11596B
LV11596B LVP-96-226A LV960226A LV11596B LV 11596 B LV11596 B LV 11596B LV 960226 A LV960226 A LV 960226A LV 11596 B LV11596 B LV 11596B
Authority
LV
Latvia
Prior art keywords
salt
cetrorelix
peptide
acid
embonate
Prior art date
Application number
LVP-96-226A
Other languages
English (en)
Other versions
LV11596A (lv
Inventor
Juergen Engel
Karin Klokkers-Bethke
Thomas Reissman
Peter Hilgard
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/661,017 external-priority patent/US5773032A/en
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of LV11596A publication Critical patent/LV11596A/lv
Publication of LV11596B publication Critical patent/LV11596B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A61K38/105—Bombesin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (7)

  1. LV 11596 IZGUDROJUMA FORMULA 1. Vāji šķīstošs LHRH analoga sāls, kur sāļa daļiņu izmērs ir pārsvarā starp 5 un 200 pm, atšķiras ar to, ka LHRH analogs ir cetroreliks, 5 aivtareliks, ganireliks, antids vai A-75998.
  2. 2. Sāls saskaņā ar 1. punktu, kas atšķiras ar to, ka sāļa daļiņu izmērs ir pārsvarā starp 10 un 15Ό pm. 10
  3. 3. Sāls saskaņā ar 1. punktu, kas atšķiras ar to, ka sāļa daļiņu izmērs ir pārsvarā starp 20 un 125 pm.
  4. 4. Vāji šķīstošs bombezīna analoga sāls, atšķiras ar to, ka sāļa daļiņu diametrs ir pārsvarā starp 5 un 200 pm. 15
  5. 5. Sāls saskaņā ar jebkuru no 1.-4. punktiem, kas atšķiras ar to, ka sāls ir embonijskābes sāls.
  6. 6. Farmaceitiska kompozīcija, kas satur sāli saskaņā ar jebkuru no 1 .-5. 20 punktiem.
  7. 7. Sāļa saskaņā ar jebkuru no 1.-5. punktiem izmantošana medikamenta ražošanai.
LVP-96-226A 1993-12-09 1996-07-09 Long-acting injection susoensions and a process for their preparation LV11596B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4342092A DE4342092B4 (de) 1993-12-09 1993-12-09 Langwirkende Injektionssuspension und Verfahren zur Herstellung
PCT/EP1994/003904 WO1995015767A1 (en) 1993-12-09 1994-11-25 Long-acting injection suspensions and a process for their preparation
US08/661,017 US5773032A (en) 1993-12-09 1996-06-10 Long-acting injection suspensions and a process for their preparation

Publications (2)

Publication Number Publication Date
LV11596A LV11596A (lv) 1996-12-20
LV11596B true LV11596B (en) 1997-06-20

Family

ID=25931926

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-96-226A LV11596B (en) 1993-12-09 1996-07-09 Long-acting injection susoensions and a process for their preparation

Country Status (27)

Country Link
EP (1) EP0732934B1 (lv)
JP (1) JPH09509145A (lv)
CN (2) CN1248732C (lv)
AT (1) ATE310530T1 (lv)
AU (1) AU677748B2 (lv)
BR (1) BR9408272A (lv)
CZ (1) CZ291025B6 (lv)
DE (1) DE4342092B4 (lv)
DK (1) DK0732934T3 (lv)
EE (1) EE03224B1 (lv)
EG (1) EG20787A (lv)
ES (1) ES2251715T3 (lv)
FI (1) FI116121B (lv)
HK (1) HK1063746A1 (lv)
HR (1) HRP940978B1 (lv)
HU (1) HU217081B (lv)
IL (1) IL111928A (lv)
LV (1) LV11596B (lv)
NO (1) NO318984B1 (lv)
NZ (1) NZ277239A (lv)
PL (1) PL186929B1 (lv)
RO (1) RO119343B1 (lv)
RS (1) RS49511B (lv)
RU (1) RU2152222C1 (lv)
SK (2) SK284981B6 (lv)
WO (1) WO1995015767A1 (lv)
ZA (1) ZA949798B (lv)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
DE69434553T2 (de) * 1993-12-09 2006-08-10 Zentaris Gmbh Lang wirkende injektionssuspensionen von lhrh-analogen und ein verfahren für ihre herstellung
AU5678398A (en) * 1997-01-29 1998-08-18 Takeda Chemical Industries Ltd. Sustained-release microspheres, their production and use
DE10040700A1 (de) * 2000-08-17 2002-02-28 Asta Medica Ag Salze von biologisch aktiven Peptiden, ihre Herstellung und Verwendung
WO2002047722A1 (fr) * 2000-12-15 2002-06-20 Takeda Chemical Industries, Ltd. Compositions medicinales agoniste ou antagoniste de la gonadoliberine non peptidyl, methode de production et utilisation desdites compositions
TW200526267A (en) 2001-06-29 2005-08-16 Takeda Chemical Industries Ltd Controlled release composition and method of producing the same
US7098305B2 (en) 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
EP1674082A1 (de) 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
WO2008075762A1 (en) 2006-12-18 2008-06-26 Takeda Pharmaceutical Company Limited Sustained-release composition and method for producing the same
WO2011060352A1 (en) * 2009-11-16 2011-05-19 Ipsen Pharma S.A.S. Pharmaceutical compositions of melanocortin receptor ligands
CN102504018A (zh) * 2011-10-28 2012-06-20 沈阳药科大学 可持续释放的蜂毒肽帕莫酸盐及其制剂
AU2017242867B9 (en) 2016-03-29 2019-07-04 Shanghai Synergy Pharmaceutical Sciences Co., Ltd Vortioxetine pamoic acid salt and crystal form thereof
CN108969478A (zh) * 2018-08-29 2018-12-11 江南大学 一种美金刚难溶盐缓释注射剂及其制备方法
CN110003195B (zh) * 2019-05-21 2020-05-26 湖北中医药大学 鲁拉西酮晶体及其制备方法和在注射给药系统中的应用
CN112569340A (zh) * 2020-12-31 2021-03-30 苏州素仕生物科技有限公司 一种无菌布舍瑞林注射液及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3852422A (en) * 1971-06-26 1974-12-03 Serono Ist Farm Long-active gonadotropins
NZ181036A (en) * 1975-06-12 1978-12-18 A Schally Luteinising hormone releasing hormone analogues and intermediates therefor
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
FR2647677B1 (fr) * 1989-05-31 1991-09-27 Roussel Uclaf Nouvelles micro-proteines, procede de preparation et application a titre de medicaments de ces nouvelles micro-proteines
CH679207A5 (lv) * 1989-07-28 1992-01-15 Debiopharm Sa
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.

Also Published As

Publication number Publication date
WO1995015767A1 (en) 1995-06-15
PL186929B1 (pl) 2004-04-30
NO961877D0 (no) 1996-05-09
FI962354A (fi) 1996-06-06
CZ142096A3 (en) 1996-12-11
IL111928A0 (en) 1995-03-15
RO119343B1 (ro) 2004-08-30
HU9601584D0 (en) 1996-08-28
DE4342092A1 (de) 1995-06-14
HRP940978A2 (en) 1997-02-28
CN1248732C (zh) 2006-04-05
FI962354A0 (fi) 1996-06-06
CN1136779A (zh) 1996-11-27
SK284980B6 (sk) 2006-03-02
DK0732934T3 (da) 2006-03-27
IL111928A (en) 1999-11-30
YU72194A (sh) 1997-03-07
EE03224B1 (et) 1999-10-15
EP0732934B1 (en) 2005-11-23
JPH09509145A (ja) 1997-09-16
ATE310530T1 (de) 2005-12-15
FI116121B (fi) 2005-09-30
NZ277239A (en) 1997-03-24
SK284981B6 (sk) 2006-03-02
PL314913A1 (en) 1996-09-30
RU2152222C1 (ru) 2000-07-10
ES2251715T3 (es) 2006-05-01
CZ291025B6 (cs) 2002-12-11
HRP940978B1 (en) 2006-08-31
EP0732934A1 (en) 1996-09-25
CN1136916C (zh) 2004-02-04
RS49511B (sr) 2006-10-27
BR9408272A (pt) 1996-12-17
ZA949798B (en) 1995-08-18
AU677748B2 (en) 1997-05-01
SK66796A3 (en) 1997-08-06
DE4342092B4 (de) 2007-01-11
CN1494919A (zh) 2004-05-12
EG20787A (en) 2000-02-29
LV11596A (lv) 1996-12-20
HUT75712A (en) 1997-05-28
HK1063746A1 (en) 2005-01-14
AU1219995A (en) 1995-06-27
NO318984B1 (no) 2005-05-30
HU217081B (hu) 1999-11-29
NO961877L (no) 1996-05-09

Similar Documents

Publication Publication Date Title
US5773032A (en) Long-acting injection suspensions and a process for their preparation
CA2198917C (en) Sustained release of peptides from pharmaceutical compositions
EP1011648B1 (en) Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer
FI116196B (fi) Menetelmä jatkuvasti vapauttavan valmisteen tuottamiseksi
EP0732934B1 (en) Long-acting injection suspensions of an lhrh analogue and a process for their preparation
EP3576771B1 (en) Compositions and methods for long term release of ganadotropin-releasing hormone (gnrh) antagonists
US20080108778A1 (en) Sustained-release composition and process for producing the same
EP1404357B1 (en) Gonadotropin releasing hormone antagonist in gel-forming concentrations
KR20080089643A (ko) 안정성이 강화된 약학 조성물
KR20190036449A (ko) 지속형 팔미트산 결합 GnRH 유도체 및 이를 포함하는 약제학적 조성물
KR100344330B1 (ko) 지속성주사현탁제
MXPA00001592A (en) Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer